New York, New York, – November 19, 2020 – Click Therapeutics announced today that Solera Health, the premier platform for addressing chronic conditions, will add Clickotine®, a clinically validated, fully digital smoking cessation program, for members of Blue Shield of California.

Clickotine is a comprehensive digital therapeutic for smoking cessation that can be downloaded on a smartphone. The program provides an individualized program that is fully integrated with nicotine replacement therapy. Through the Solera/Clickotine collaboration, Blue Shield of California’s members enrolled in its Wellvolution platform can access the clinically validated program at no additional cost to them.

The new partnership builds on Clickotine’s recent expansion into the not-for-profit health plan market. The agreement with Solera also marks Clickotine’s most significant entry into value-based, pay for performance agreements designed to improve care while also lowering costs.

“Smoking takes a troubling toll on both the health and the costs of care for those who smoke; in the United States alone, 16 million people live with diseases brought on by smoking. Ensuring that Blue Shield of California members have access to a fully digital, clinically validated smoking cessation program such as Clickotine, is essential to improving patient’s health and lowering costs,” said Ross Muken, chief financial officer at Click Therapeutics. “Clickotine empowers Blue Shield of California members to embark on a personalized program, allowing them to stop smoking on their own terms and in their own time. Perhaps most importantly, it is proven to work with long lasting results and can be accessed and completed entirely remotely.”

“Solera is pleased to add Clickotine to our roster of best-in-class evidence-based lifestyle intervention providers for tobacco cessation,” said Mary Langowski, CEO at Solera Health. “We carefully vet all of the programs we add to our network and Clickotine has a proven track record of successfully helping people reach their quit goals.”

Solera is committed to changing lives by guiding people to better health in their communities. The company has built a dynamic platform that provides intensive, evidence-based lifestyle, behavioral, and social interventions to impact the costliest chronic conditions in the country. Solera’s marketplace strategically matches consumers to curated disease prevention with a network of community organizations and digital therapeutics providers delivering the most meaningful health outcomes. Solera is HITRUST certified, the most prestigious certification for meeting healthcare regulations and requirements for protecting and securing sensitive private healthcare information. For more information, visit Solera at www.soleranetwork.com.

Click Therapeutics, Inc. develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. We are expanding the possibilities of medicine with Digital Therapeutics™ that combine clinical science with the power of software to create a new way to treat disease.  

Operating at the intersection of biology and technology, we use a proprietary platform-based approach to therapeutic development that leverages patient-centric design principles and innovative AI-based technologies to deliver a unique combination of engagement and clinical outcomes, consistently. Digital therapeutics on Click’s platform are regulated, clinically validated prescription mobile applications that can address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. 

Click Therapeutics, in collaboration with Otsuka, developed the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms, Rejoyn™. In October 2024, in response to FDA guidance on prescription drug use-related software (PDURS), we launched Click SE™ to extend our digital therapeutics platform and expertise to the development of software-enhanced drug™ therapies that combine software with pharmacotherapy to offer added clinically meaningful benefit to patients.

Our commitment to advancing digital medicine means we continually improve our platform technologies, ensuring we stay at the forefront of cognitive, behavioral, and neuromodulatory therapeutic innovation, to achieve the best possible outcomes for patients. Our diverse team of innovators—spanning clinicians, researchers, technologists, designers and more—works together to create cutting-edge digital therapeutics, united in the mission to transform patient care. For more information, visit www.clicktherapeutics.com and connect with us on LinkedIn.